BerGenBio ASA (BRRGF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BerGenBio ASA (BRRGF) with AI Score 74/100 (Buy). BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing drugs for immune evasive, drug resistant, and metastatic cancers, as well as respiratory diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026BerGenBio ASA (BRRGF) Healthcare & Pipeline Overview
BerGenBio ASA, a Norwegian clinical-stage biopharmaceutical company, specializes in developing AXL inhibitor therapies like Bemcentinib for cancers and respiratory diseases. With a focus on immune evasion and drug resistance, BerGenBio navigates the competitive biotech landscape through strategic collaborations and Phase II clinical trials, targeting unmet medical needs.
Investment Thesis
BerGenBio ASA presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead drug candidate, Bemcentinib, targeting the AXL receptor, is in Phase II clinical trials for multiple cancer indications and COVID-19, representing a significant potential value driver. Positive clinical trial results could lead to substantial stock appreciation. The collaboration with Merck & Co. provides validation and potential for future partnerships. However, the company's negative profit margin of -1990.4% and reliance on clinical trial success pose substantial risks. The company's small size and limited resources also present operational challenges. Investors should closely monitor clinical trial data and partnership developments to assess the company's progress and potential for long-term growth.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $9.49 billion, reflecting investor expectations for future growth and potential success of its clinical trials.
- Gross Margin of 98.1%, indicating strong potential profitability if clinical trials are successful and products are commercialized.
- P/E Ratio of -16.51, reflecting the company's current lack of profitability due to its clinical-stage status.
- Beta of 1.31, indicating higher volatility compared to the overall market, typical for biotechnology companies with ongoing clinical trials.
- Lead candidate Bemcentinib in Phase II clinical development across multiple cancer indications, representing a key value driver.
Competitors & Peers
Strengths
- Proprietary AXL inhibitor technology.
- Lead candidate Bemcentinib in Phase II clinical trials.
- Collaboration agreement with Merck & Co.
- Focus on addressing unmet medical needs in oncology and respiratory diseases.
Weaknesses
- Clinical-stage company with no currently approved products.
- Negative profit margin and reliance on external funding.
- Small size and limited resources.
- High dependence on clinical trial outcomes.
Catalysts
- Ongoing: Phase II clinical trial results for Bemcentinib in non-small cell lung cancer.
- Ongoing: Phase II clinical trial results for Bemcentinib in acute myeloid leukemia.
- Ongoing: Phase II clinical trial results for Bemcentinib in myelodysplastic syndrome.
- Upcoming: Potential announcement of new strategic partnerships or licensing agreements.
- Upcoming: Publication of scientific data related to AXL inhibition and BerGenBio's drug candidates.
Risks
- Potential: Clinical trial failures for Bemcentinib or tilvestamab.
- Potential: Regulatory hurdles and delays in obtaining drug approvals.
- Ongoing: Competition from other biopharmaceutical companies developing similar therapies.
- Ongoing: Dependence on external funding and potential dilution of existing shareholders.
- Potential: Patent expiration and generic competition for BerGenBio's drug candidates.
Growth Opportunities
- Expansion of Bemcentinib into New Cancer Indications: Bemcentinib, BerGenBio's lead candidate, holds potential for expansion into additional cancer indications beyond its current Phase II trials. The global cancer therapeutics market is projected to reach $286 billion by 2028. Positive clinical trial results in new cancer types could significantly increase Bemcentinib's market potential. This expansion strategy could be pursued within the next 2-3 years, contingent on ongoing trial outcomes.
- Advancement of Tilvestamab to Later-Stage Clinical Trials: Tilvestamab, BerGenBio's anti-AXL antibody, is currently in Phase Ib clinical trials. Successful completion of Phase Ib and progression to Phase II trials would represent a significant milestone. The antibody therapeutics market is expected to grow, driven by the increasing demand for targeted therapies. Advancement of Tilvestamab could occur within the next 3-5 years, depending on trial results and funding.
- Strategic Partnerships and Licensing Agreements: BerGenBio can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. The pharmaceutical industry is characterized by collaborations and partnerships to share risks and resources. Securing such agreements could provide BerGenBio with funding and expertise to advance its pipeline. These partnerships could materialize within the next 1-2 years.
- Expansion into Respiratory Disease Therapies: BerGenBio's research and development efforts in respiratory diseases, including COVID-19, represent a growth opportunity. The respiratory disease therapeutics market is substantial, driven by the prevalence of conditions like asthma, COPD, and infectious respiratory illnesses. Success in developing effective therapies for these diseases could generate significant revenue. This expansion could yield results in the next 2-4 years, depending on clinical trial progress.
- Exploration of AXL Inhibitor Combinations: BerGenBio can explore the potential of combining its AXL inhibitors with other cancer therapies, such as chemotherapy or immunotherapy. Combination therapies are increasingly common in oncology, aiming to improve treatment efficacy and overcome drug resistance. Positive results from combination studies could lead to new treatment regimens and market opportunities. This exploration could begin within the next 1-2 years, with clinical trial data emerging over the subsequent years.
Opportunities
- Expansion of Bemcentinib into new cancer indications.
- Advancement of tilvestamab to later-stage clinical trials.
- Strategic partnerships and licensing agreements.
- Expansion into respiratory disease therapies.
Threats
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from other biopharmaceutical companies.
- Patent expiration and generic competition.
Competitive Advantages
- Proprietary AXL inhibitor technology: BerGenBio has developed a portfolio of AXL inhibitors, including Bemcentinib and tilvestamab, which are protected by patents.
- Clinical trial expertise: The company has experience in conducting clinical trials, which is essential for drug development.
- Collaboration with Merck & Co.: The collaboration with Merck & Co. provides validation and access to resources.
- Focus on a specific target: BerGenBio's focus on AXL inhibition allows it to develop specialized expertise and potentially achieve superior efficacy compared to broader-spectrum therapies.
About BRRGF
BerGenBio ASA, founded in 2007 and based in Bergen, Norway, is a clinical-stage biopharmaceutical company dedicated to developing innovative drugs for the treatment of cancer and respiratory diseases. The company's primary focus is on addressing immune evasive, drug resistant, and metastatic cancers. BerGenBio's lead candidate, Bemcentinib, is a bio-available small molecule AXL inhibitor currently undergoing Phase II clinical development across various cancer indications and COVID-19. Bemcentinib aims to improve patient outcomes by targeting the AXL receptor tyrosine kinase, a key driver of tumor growth, survival, and drug resistance. The company's Phase II clinical trial program encompasses non-small cell lung cancer, acute myeloid leukemia, and myelodysplastic syndrome, as well as COVID-19. In addition to Bemcentinib, BerGenBio is also developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. This antibody is designed to block AXL signaling and enhance the anti-tumor immune response. BerGenBio has established a collaboration agreement with Merck & Co. for clinical trials, enhancing its research and development efforts. With a lean team of 13 employees, BerGenBio is focused on advancing its pipeline of novel therapies to address significant unmet medical needs in oncology and respiratory diseases.
What They Do
- Develop drugs to treat immune evasive cancers.
- Develop drugs to treat drug resistant cancers.
- Develop drugs to treat metastatic cancers.
- Develop drugs to treat respiratory diseases.
- Focus on AXL (AXL receptor tyrosine kinase) inhibition as a therapeutic strategy.
- Conduct Phase II clinical trials for Bemcentinib in various cancer indications.
- Develop anti-AXL antibodies like tilvestamab.
Business Model
- Develops proprietary drug candidates targeting AXL inhibition.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approval for its drug candidates from agencies like the FDA and EMA.
- Potentially commercializes its drugs directly or through partnerships with larger pharmaceutical companies.
Industry Context
BerGenBio ASA operates within the competitive biotechnology industry, characterized by high R&D costs, lengthy regulatory approval processes, and significant clinical trial risks. The industry is driven by innovation and the development of novel therapies for unmet medical needs. The global biotechnology market is projected to reach $3.87 trillion by 2030, growing at a CAGR of 12.3% from 2022. BerGenBio competes with other biopharmaceutical companies, including DOGP, FTHWF, GHSI, IPCIF, and IVITF, all vying for market share in oncology and respiratory disease therapeutics. Success in this industry hinges on clinical trial outcomes, regulatory approvals, and strategic partnerships.
Key Customers
- Patients with cancer (non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome).
- Patients with respiratory diseases (COVID-19).
- Healthcare providers who prescribe and administer BerGenBio's drugs.
- Pharmaceutical companies that may partner with BerGenBio for development and commercialization.
Financials
Chart & Info
BerGenBio ASA (BRRGF) stock price: Price data unavailable
Latest News
No recent news available for BRRGF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BRRGF.
Price Targets
Wall Street price target analysis for BRRGF.
MoonshotScore
What does this score mean?
The MoonshotScore rates BRRGF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Oystein Soug
CEO
Oystein Soug serves as the CEO of BerGenBio ASA. Information regarding his detailed career history, education, and previous roles is not available in the provided data. His credentials and specific expertise remain unknown based on the current context.
Track Record: Oystein Soug currently manages 13 employees at BerGenBio ASA. Specific achievements, strategic decisions, and company milestones under his leadership are not detailed in the provided data. Therefore, a comprehensive assessment of his track record is not possible.
BRRGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BerGenBio ASA may not meet the minimum financial or reporting standards required for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited financial disclosure and may be subject to greater risks due to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, companies in bankruptcy, or those unwilling or unable to meet higher reporting standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or mismanagement compared to companies on major exchanges.
- Limited regulatory oversight and investor protection.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Determine the company's cash flow and financial stability.
- Understand the company's capital structure and potential dilution.
- Consult with a qualified financial advisor before investing.
- Clinical-stage biopharmaceutical company with ongoing clinical trials.
- Collaboration agreement with Merck & Co.
- Focus on developing innovative therapies for unmet medical needs.
- Presence of a CEO and a team of employees.
- Incorporated in 2007, suggesting a history of operations.
What Investors Ask About BerGenBio ASA (BRRGF)
What does BerGenBio ASA do?
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and respiratory diseases. The company's lead candidate, Bemcentinib, is a small molecule AXL inhibitor currently in Phase II clinical development for various cancer indications and COVID-19. BerGenBio also develops anti-AXL antibodies like tilvestamab, which is in Phase Ib clinical trials. The company aims to address immune evasive, drug resistant, and metastatic cancers through its targeted therapies, potentially improving patient outcomes.
What do analysts say about BRRGF stock?
AI analysis is currently pending for BRRGF stock. Therefore, a summary of analyst consensus, key valuation metrics, and growth considerations is unavailable at this time. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Further information will be available once the AI analysis is complete.
What are the main risks for BRRGF?
BerGenBio ASA faces several key risks inherent to the biotechnology industry. Clinical trial failures for its drug candidates, Bemcentinib and tilvestamab, represent a significant risk. Regulatory hurdles and delays in obtaining drug approvals from agencies like the FDA and EMA could also impact the company's timeline and financial prospects. Competition from other biopharmaceutical companies developing similar therapies poses a threat to BerGenBio's market share. The company's reliance on external funding and potential patent expiration also present ongoing risks.
What are the key factors to evaluate for BRRGF?
BerGenBio ASA (BRRGF) currently holds an AI score of 74/100, indicating high score. Key strength: Proprietary AXL inhibitor technology.. Primary risk to monitor: Potential: Clinical trial failures for Bemcentinib or tilvestamab.. This is not financial advice.
How frequently does BRRGF data refresh on this page?
BRRGF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BRRGF's recent stock price performance?
Recent price movement in BerGenBio ASA (BRRGF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary AXL inhibitor technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BRRGF overvalued or undervalued right now?
Determining whether BerGenBio ASA (BRRGF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BRRGF?
Before investing in BerGenBio ASA (BRRGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided data and may not be exhaustive.
- AI analysis is pending and may provide further insights.